Search

Relay Therapeutics Inc

Suletud

SektorTervishoid

18.1 0.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.02

Max

18.2

Põhinäitajad

By Trading Economics

Sissetulek

2M

-82M

Aktsiakasum

-0.37

Kasumimarginaal

-23,916.286

Töötajad

218

EBITDA

1.9M

-81M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+60.31% upside

Turustatistika

By TradingEconomics

Turukapital

719M

4.5B

Eelmine avamishind

17.93

Eelmine sulgemishind

18.1

Relay Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2026, 21:07 UTC

Relay Therapeutics, Inc. shares are rising, supported by gains in the Biotechnology sub-sector, despite earlier pulling back from a session high amid volatility.

12. nov 2026, 22:11 UTC

Relay Therapeutics, Inc. finished lower in after-market trading, continuing a trend of declines and remaining below its 20-day moving average.

10. nov 2026, 21:07 UTC

Relay Therapeutics, Inc. shares declined sharply, reversing from an early peak and finishing near session lows, reflecting a weaker performance since Monday's close.

9. nov 2026, 21:03 UTC

Relay Therapeutics, Inc. shares are advancing sharply, trading with unusually high volume and well above its 20-day moving average.

6. nov 2026, 21:02 UTC

News

Jones Trading analyst Boris Peaker raised the price target on Relay Therapeutics to $31.00 from $20.00 while maintaining a Buy rating.

5. nov 2026, 21:04 UTC

Relay Therapeutics, Inc. shares are declining amid a broader market downturn, remaining under pressure and trading near the lower end of their one-month range.

4. nov 2026, 22:02 UTC

News

Relay Therapeutics reported a net loss of $81.7 million, or $0.37 per share, for Q3 2026, better than the expected $0.40 loss.

3. nov 2026, 20:46 UTC

Relay Therapeutics, Inc. is trading higher on Tuesday after reaching a peak earlier in the session, though it remains below its 20-day moving average.

2. nov 2026, 21:04 UTC

Shares of Relay Therapeutics, Inc. fell sharply, reversing recent upward momentum amid a broader decline in the market.

30. okt 2026, 20:03 UTC

Relay Therapeutics, Inc. shares fell sharply after briefly rising earlier in the session.

29. okt 2026, 20:07 UTC

Shares of Relay Therapeutics, Inc. declined, pulling back from an earlier session high, as part of a broader market trend closing lower.

28. okt 2026, 23:36 UTC

News

Relay Therapeutics will report its Q3 2026 financial results on November 4, 2026, after the market close, amid ongoing development of zovegalisib.

27. okt 2026, 20:31 UTC

Relay Therapeutics, Inc. is seeing modest gains in after-market trading, rising from a low shortly after the market closed and trading above its 20-day moving average.

26. okt 2026, 19:46 UTC

Relay Therapeutics Inc shares are declining, continuing a downward trend observed over the last three sessions, despite a brief peak earlier in the session.

23. okt 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining amid a broader market downturn, despite an earlier rebound from a session low.

22. okt 2026, 19:56 UTC

Social Media

Relay Therapeutics Inc shares are modestly lower, having retraced from an early gain and currently positioned around the midpoint of its one-month trading range.

21. okt 2026, 19:36 UTC

Relay Therapeutics Inc shares are declining, pulling back from an earlier peak, and are modestly lower since Tuesday's close amid session volatility.

20. okt 2026, 20:01 UTC

Relay Therapeutics Inc shares are advancing sharply, continuing an upward trend with a notable increase since Monday's close, reaching a peak before the close.

19. okt 2026, 19:46 UTC

Relay Therapeutics Inc shares are sharply higher.

16. okt 2026, 20:02 UTC

Relay Therapeutics Inc shares are declining, reversing a trend of higher daily closes observed in recent sessions, reflecting a shift in momentum.

15. okt 2026, 19:46 UTC

Relay Therapeutics Inc is trading higher, having reached a peak return during Thursday's session.

14. okt 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining, positioned near the lower end of their one-month range and below the 20-day moving average.

13. okt 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining, following significant volatility and a drop to their lowest point mid-session, trading well below the 20-day moving average.

12. okt 2026, 22:02 UTC

Relay Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a decline amid broader weakness in the biotechnology sector.

9. okt 2026, 20:06 UTC

Relay Therapeutics Inc shares are advancing, continuing a recovery trend after prior declines, despite earlier pulling back from a notable peak in today's session.

8. okt 2026, 23:01 UTC

Relay Therapeutics Inc shares are sharply lower in after-market trading, continuing a trend of declines following four consecutive lower daily closes.

7. okt 2026, 19:35 UTC

Relay Therapeutics Inc shares fell sharply, reaching their lowest point around mid-day, despite a brief rebound earlier in the session.

6. okt 2026, 20:00 UTC

Relay Therapeutics Inc shares fell sharply, breaking a trend of higher daily closes amid unusually high volume and a broader downturn in the biotechnology sector.

5. okt 2026, 19:16 UTC

Relay Therapeutics Inc is gaining, recovering from an earlier low and continuing an upward trend after three consecutive sessions of positive performance.

2. okt 2026, 21:01 UTC

Relay Therapeutics Inc declined during after-market hours, moving lower from Friday's close after initially starting with a slight gain.

Võrdlus sarnastega

Hinnamuutus

Relay Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

60.31% tõus

12 kuu keskmine prognoos

Keskmine 29 USD  60.31%

Kõrge 31 USD

Madal 26 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Relay Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat